In vivo study of newly developed albumin-conjugated urate oxidase for gout treatment

In vivo study of newly developed albumin-conjugated urate oxidase for gout treatment

Abstract Background Exogenously providing engineered Uox with enhanced half-life is one of the important urate-lowering treatments for gout. The potential of PAT101, a recombinant human albumin (rHA)-conjugated variant, was evaluated and compared as a novel gout treatment through various in vivo stu...

Full description

Bibliographic Details
Main Authors: Jeonghaeng Cho, Byungseop Yang, Jae Hun Lee, Hyunwoo Kim, Hyeongseok Kim, Eun Byeol Go, Dong-ho Bak, Su Jin Park, Inchan Kwon, Jong-il Choi, Kyunghee Lee
Format: Article
Language:English
Published: BMC 2023-12-01
Series:Arthritis Research & Therapy
Subjects:
Gout
Urate oxidase
AfUox
rHA
Site-specific conjugation
IEDDA
Online Access:https://doi.org/10.1186/s13075-023-03231-3

Internet

https://doi.org/10.1186/s13075-023-03231-3

Similar Items